Date: April 23, 2020

RE: Discontinuation of Sale and Distribution of PRCoumadin® (warfarin sodium) Tablets, for oral use.

Dear Healthcare Professional,

Bristol-Myers Squibb Canada would like to inform you that the sale and distribution of all strengths of Coumadin® (warfarin sodium) tablets will be discontinued in the United States, Canada, Latin America, and Saudi Arabia, due to an unexpected manufacturing issue that could not be resolved expeditiously. Based on stock availability and expiration dates, we anticipate discontinuation of Coumadin® strengths to begin on June 1, 2020. Full discontinuation of all strengths is expected by August 31, 2020.

This voluntary action is the result of an unexpected manufacturing issue that cannot be resolved and is not the result of any quality, safety or efficacy issue regarding the product.

Indication:
COUMADIN (warfarin sodium) is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, atrial fibrillation with embolization, and as an adjunct in the prophylaxis of systemic embolism after myocardial infarction, including stroke and reinfarction.

For your patients currently using Coumadin® (warfarin sodium) tablets, healthcare providers will be required to consider alternatives. BMS cannot recommend a specific product. Prescribing an alternate product is the clinical decision of the healthcare professional in consultation with the patient. In Canada, therapeutic alternatives, including generics, are available.

If you have questions or require additional information regarding the discontinuation of Coumadin® Tablets, please contact Bristol-Myers Squibb Canada at 1-800-267-0005 or via e-mail at otc.canada@bms.com.

For medical information requests, please contact our Medical Information Services at 1-866-463-6267 or at medical.canada@bms.com.

Sincerely,

Joseph Atallah
Head, Medical Affairs
Bristol Myers Squibb Canada